申请人:Dainippon Sumitomo Pharma Co., Ltd.
公开号:EP1829877A1
公开(公告)日:2007-09-05
Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I)
wherein the solid line and dotted line between A1 and A2 represents a double bond (A1=A2) or the like; A1 is C(R4) or the like; A2 is nitrogen atom or the like; R1 is hydrogen atom, optionally substituted alkly group, or the like; R2 is hydrogen atom, optionally substituted alkyl group, or the like; R3 is hydrogen atom, halogen atom, or the like; R4 is hydrogen atom, hydroxyl, halogen atom, or the like; and Y is a group represented by the general formula (A) or the like; (A)
[wherein m1 is 0, 1, 2 or 3; and the group (A) may be freed from R6 or substituted with one or two R6's which are each independently halogen atom or the like.]
通式(I)代表的化合物、其原药或二者的药学上可接受的盐类具有较高的 DPP-IV 抑制活性,并在安全性、毒性等方面有所改善:(I)
其中 A1 和 A2 之间的实线和虚线代表双键(A1=A2)或类似物;A1 是 C(R4)或类似物;A2 是氮原子或类似物;R1 是氢原子、任选取代的烷基或类似物;R2 是氢原子、任选取代的烷基或类似物;R3 是氢原子、卤素原子或类似物;R4 是氢原子、羟基、卤素原子或类似物;Y 是通式(A)所代表的基团或类似物; (A)
[其中 m1 是 0、1、2 或 3;基团 (A) 可以不含 R6,也可以被一个或两个各自独立为卤素原子或类似物的 R6 取代。]